Teva Neuroscience Inc v. Alkem Laboratories Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Teva Neuroscience, Inc. (Delaware) and Auspex Pharmaceuticals LLC (Delaware)
  • Defendant: Alkem Laboratories Limited (India) and Ascend Laboratories, LLC (New Jersey)
  • Plaintiff's Counsel: Walsh Pizzi Oreilly Falanga LLP
• Case Identification: 2:26-cv-06612, D.N.J., 06/05/2026
• Venue Allegations: Venue is alleged to be proper in the District of New Jersey on the grounds that Defendant Alkem Laboratories Limited is a foreign corporation subject to personal jurisdiction in the district, and Defendant Ascend Laboratories, LLC, resides in New Jersey and has a regular and established place of business there.
• Core Dispute: Plaintiffs allege that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market generic versions of Plaintiffs' AUSTEDO® XR (deutetrabenazine) tablets constitutes an act of infringement of twelve U.S. patents covering the drug's composition, formulation, and methods of use.
• Technical Context: The technology relates to deutetrabenazine, a deuterated form of tetrabenazine, used for treating hyperkinetic movement disorders such as chorea associated with Huntington's disease and tardive dyskinesia.
• Key Procedural History: This is a Hatch-Waxman action initiated under 35 U.S.C. § 271(e)(2) following Defendants' submission of ANDA No. 221495 containing a Paragraph IV certification, asserting that the patents-in-suit are invalid, unenforceable, or will not be infringed by the proposed generic products. The complaint was filed before the expiration of the 45-day period triggered by Plaintiffs' receipt of Defendants' notice letters.

Case Timeline

Date	Event
2012-09-18	U.S. Patent No. 9,550,780 Priority Date
2015-03-06	U.S. Patent Nos. 10,959,996; 11,357,772; 11,446,291; 11,564,917; 11,648,244; 12,016,858 Priority Date
2017-01-24	U.S. Patent No. 9,550,780 Issued
2017-03-15	U.S. Patent Nos. 11,179,386; 11,813,232 Priority Date
2020-06-10	U.S. Patent Nos. 11,311,488; 12,589,075; 12,599,598 Priority Date
2021-03-30	U.S. Patent No. 10,959,996 Issued
2021-11-23	U.S. Patent No. 11,179,386 Issued
2022-04-26	U.S. Patent No. 11,311,488 Issued
2022-06-14	U.S. Patent No. 11,357,772 Issued
2022-09-20	U.S. Patent No. 11,446,291 Issued
2023-01-31	U.S. Patent No. 11,564,917 Issued
2023-05-16	U.S. Patent No. 11,648,244 Issued
2023-11-14	U.S. Patent No. 11,813,232 Issued
2024-06-25	U.S. Patent No. 12,016,858 Issued
2026-03-31	U.S. Patent No. 12,589,075 Issued
2026-04-14	U.S. Patent No. 12,599,598 Issued
2026-04-23	Alkem's First Notice Letter to Plaintiffs
2026-05-18	Alkem's Second Notice Letter to Plaintiffs
2026-06-05	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,550,780 - Formulations Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monamine Transporter 2

The Invention Explained

• Problem Addressed: The complaint does not contain the specification of the '780 patent to detail the problem addressed. However, the claims suggest a focus on obtaining a specific, stable crystalline form of the active pharmaceutical ingredient.
• The Patented Solution: The patent claims a specific crystalline form of d6-tetrabenazine, designated "Form I" Compl. ¶29 This form is defined by a set of characteristic peaks in an X-ray diffractogram, which provides a unique fingerprint for this particular solid-state arrangement of the molecule Compl. ¶29 By defining and claiming this specific form, the invention provides a composition of matter with potentially distinct and advantageous properties, such as stability, solubility, or manufacturability, compared to other amorphous or crystalline forms.
• Technical Importance: In pharmaceutical development, identifying and controlling the specific crystalline form (polymorph) of a drug is critical for ensuring consistent product quality, performance, and stability.

Key Claims at a Glance

• The complaint asserts infringement of at least claim 1 Compl. ¶108
• Independent Claim 1 contains the following essential elements:
  • A compound that is crystalline d6-tetrabenazine Form I.
  • Having a deuterium enrichment of no less than about 1%.
  • Having an X-ray diffractogram comprising peaks, in terms of 2θ±0.2, at 6.5, 12.2, 14.4, 22.4 and 23.4.
  • Or a pharmaceutically acceptable salt or hydrate thereof. Compl. ¶29

U.S. Patent No. 10,959,996 - Methods for the Treatment of Abnormal Involuntary Movement Disorders

The Invention Explained

• Problem Addressed: The patent describes a need for improved compositions and dosing regimens for treating abnormal involuntary movements, noting that existing therapies like tetrabenazine have limitations '996 Patent, col. 3:1-7
• The Patented Solution: The patent provides a specific method for transitioning a patient from a daily dose of tetrabenazine to a corresponding, therapeutically effective initial dose of deutetrabenazine '996 Patent, abstract This method comprises discontinuing tetrabenazine and, on the next day, administering a specific initial dose of deutetrabenazine based on the patient's prior tetrabenazine dosage '996 Patent, col. 8:36-59 This provides a defined protocol for physicians to switch patients to the deuterated drug.
• Technical Importance: Providing a clinically-defined dose-conversion protocol facilitates the safe and effective adoption of a new drug by mitigating uncertainty for prescribing physicians and improving patient outcomes during the switch.

Key Claims at a Glance

• The complaint asserts infringement of at least claim 1 Compl. ¶118
• Independent Claim 1 contains the following essential elements:
  • A method of transitioning a human from tetrabenazine to deutetrabenazine.
  • For the treatment of chorea associated with Huntington's disease.
  • Comprising: a) discontinuing a daily amount of tetrabenazine; and b) administering an initial daily amount of deutetrabenazine the next day to the human.
  • Wherein the daily amount of tetrabenazine and the initial total daily amount of deutetrabenazine are one of eight specific dosage pairs (e.g., 12.5 mg tetrabenazine to 6 mg deutetrabenazine). Compl. ¶35

U.S. Patent No. 11,179,386 - Analogs of Deutetrabenazine, Their Preparation and Use

• Technology Synopsis: This patent claims a pharmaceutical composition in tablet form containing deutetrabenazine with a specific, low limit on the amount of a particular impurity, identified as "Compound 2." The impurity level is measured by a specific HPLC method Compl. ¶41 This addresses the need for high-purity drug products to ensure safety and efficacy.
• Asserted Claims: At least claim 1 Compl. ¶128
• Accused Features: The proposed generic deutetrabenazine tablets are alleged to infringe Compl. ¶128

U.S. Patent No. 11,311,488 - Osmotic Dosage Forms Comprising Deutetrabenazine and Methods of Use Thereof

• Technology Synopsis: This patent claims a once-daily osmotic oral dosage form for deutetrabenazine. The technology involves a multi-layer tablet core (active and push layers), a semipermeable layer with a port, and an optional immediate-release coating, designed to provide controlled, extended release of the drug over a 24-hour period Compl. ¶47
• Asserted Claims: At least claim 1 Compl. ¶138
• Accused Features: The proposed generic deutetrabenazine extended-release tablets are alleged to infringe Compl. ¶138

U.S. Patent No. 11,357,772 - Methods for the Treatment of Abnormal Involuntary Movement Disorders

• Technology Synopsis: This patent claims a method for treating abnormal involuntary movement by administering an initial dose of deutetrabenazine, monitoring the patient's response and tolerability, and then titrating the dose upwards or downwards in 6 mg/day increments to achieve adequate control Compl. ¶53 This covers a dose-titration regimen for optimizing therapy.
• Asserted Claims: At least claim 1 Compl. ¶148
• Accused Features: The use of the proposed generic product as directed by its labeling is alleged to infringe Compl. ¶150

U.S. Patent No. 11,446,291 - Methods for the Treatment of Abnormal Involuntary Movement Disorders

• Technology Synopsis: This patent claims a method of transitioning a patient from tetrabenazine to deutetrabenazine for the treatment of tardive dyskinesia. The method involves specific dosage conversion pairs, similar to the '996 patent but for a different indication Compl. ¶59
• Asserted Claims: At least claim 1 Compl. ¶158
• Accused Features: The use of the proposed generic product as directed by its labeling is alleged to infringe Compl. ¶160

U.S. Patent No. 11,564,917 - Methods for the Treatment of Abnormal Involuntary Movement Disorders

• Technology Synopsis: This patent claims a method of treating tardive dyskinesia in specific patient populations defined by baseline ECG (electrocardiogram) QTcF values. The method involves administering a dose of deutetrabenazine of less than or equal to about 24 mg, where the treatment results in an improvement in motor function and a maximal QTcF increase of less than 5 ms Compl. ¶65
• Asserted Claims: At least claim 1 Compl. ¶168
• Accused Features: The use of the proposed generic product as directed by its labeling is alleged to infringe Compl. ¶170

U.S. Patent No. 11,648,244 - Methods for the Treatment of Abnormal Involuntary Movement Disorders

• Technology Synopsis: This patent claims a method of treating tardive dyskinesia in a human subject defined by age and history of dopamine receptor antagonist use. The method involves administering a total daily amount of deutetrabenazine from about 24 mg to about 48 mg, resulting in improved motor function with no clinically significant adverse event Compl. ¶71
• Asserted Claims: At least claim 1 Compl. ¶178
• Accused Features: The use of the proposed generic product as directed by its labeling is alleged to infringe Compl. ¶180

U.S. Patent No. 11,813,232 - Analogs of Deutetrabenazine, Their Preparations and Use

• Technology Synopsis: This patent claims a process for preparing a deutetrabenazine tablet that has a low level of "Compound 2" impurity after one month of storage. The process requires starting with a deutetrabenazine drug substance that itself has an even lower, specified limit of Compound 2 Compl. ¶77 This protects the final drug product's stability and purity.
• Asserted Claims: At least claims 1 and 2 Compl. ¶188
• Accused Features: The manufacture of the proposed generic product is alleged to infringe the process claim, and the product itself is alleged to infringe the product-by-process claim Compl. ¶¶188, 190

U.S. Patent No. 12,016,858 - Methods for the Treatment of Abnormal Involuntary Movement Disorders

• Technology Synopsis: This patent claims a method for treating abnormal involuntary movement that starts with an initial daily dose of 12 mg of deutetrabenazine. The method includes steps for monitoring and titrating the dose upwards or downwards in 6 mg/day increments based on efficacy and tolerability Compl. ¶84
• Asserted Claims: At least claim 1 Compl. ¶198
• Accused Features: The use of the proposed generic product as directed by its labeling is alleged to infringe Compl. ¶200

U.S. Patent No. 12,589,075 - Osmotic Dosage Forms Comprising Deutetrabenazine and Methods of Use Thereof

• Technology Synopsis: This patent claims a method of administering a once-daily osmotic dosage form of deutetrabenazine to treat a hyperkinetic movement disorder. The claim recites the structural features of the osmotic dosage form, which are substantially similar to those claimed in the '488 patent Compl. ¶90
• Asserted Claims: At least claim 1 Compl. ¶208
• Accused Features: The use of the proposed generic product as directed by its labeling is alleged to infringe Compl. ¶210

U.S. Patent No. 12,599,598 - Osmotic Dosage Forms Comprising Deutetrabenazine and Methods of Use Thereof

• Technology Synopsis: This patent claims a method for transitioning a patient from a twice-daily deutetrabenazine regimen to a once-daily osmotic dosage form regimen. The claim recites the structural features of the osmotic dosage form, which are substantially similar to those in the '488 and '075 patents Compl. ¶96
• Asserted Claims: At least claim 1 Compl. ¶218
• Accused Features: The use of the proposed generic product as directed by its labeling is alleged to infringe Compl. ¶220

III. The Accused Instrumentality

Product Identification

The accused instrumentalities are Defendants' proposed generic versions of AUSTEDO® XR (deutetrabenazine) oral extended-release tablets, identified as "Alkem's ANDA Products" Compl. ¶1

Functionality and Market Context

The complaint alleges that Alkem seeks FDA approval to market deutetrabenazine extended-release tablets in 6 mg, 12 mg, and 24 mg dosage strengths Compl. ¶100 Compl. ¶102 These products are intended to be generic equivalents to Plaintiffs' AUSTEDO® XR tablets, which are approved for treating chorea associated with Huntington's disease and tardive dyskinesia Compl. ¶3 The act of infringement alleged is the submission of ANDA No. 221495 to the FDA, which is a statutory act of infringement under the Hatch-Waxman Act designed to resolve patent disputes before the generic drug enters the market Compl. ¶1 Compl. ¶107 The complaint includes a chemical structure diagram of Deutetrabenazine Compl. p. 9

IV. Analysis of Infringement Allegations

'780 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A compound that is crystalline d6-tetrabenazine Form I...	On information and belief, the active ingredient in Alkem's ANDA Products, deutetrabenazine, will be the specific crystalline Form I.	¶108	col. 27:36-37
...having deuterium enrichment of no less than about 1%...	On information and belief, the deutetrabenazine in Alkem's ANDA Products will meet this deuterium enrichment level.	¶108	col. 27:37-38
...and having an X-ray diffractogram comprising peaks, in terms of 2θ±0.2, at 6.5, 12.2, 14.4, 22.4 and 23.4...	On information and belief, the crystalline form of deutetrabenazine in Alkem's ANDA Products will exhibit these characteristic XRD peaks.	¶108	col. 27:38-42
...or a pharmaceutically acceptable salt or hydrate thereof.	On information and belief, Alkem's ANDA Products will comprise the claimed compound or a salt or hydrate thereof.	¶108	col. 27:43-44

• Identified Points of Contention:
  • Evidentiary Questions: The core of the dispute for the '780 patent will be factual. The complaint alleges infringement on "information and belief" Compl. ¶108, which is standard at the pleading stage of an ANDA case before discovery of the ANDA's contents. The central question for the court will be whether the deutetrabenazine in Alkem's proposed product is, in fact, the specific crystalline "Form I" as defined by the patent's claims. This raises the question of what analytical data (e.g., XRD) Alkem has provided to the FDA and what it will reveal in discovery.
  • Scope Questions: A potential issue may be the scope of "about 1%" for deuterium enrichment and the "±0.2" range for the 2θ peaks Compl. ¶29 The parties may dispute whether Alkem's product, if its characteristics are near but not identical to these values, falls within the claimed range.

'996 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of transitioning a human from tetrabenazine to deutetrabenazine for the treatment of chorea associated with Huntington's disease...	On information and belief, the proposed labeling for Alkem's ANDA Products will instruct or encourage physicians to perform this transition method for this indication.	¶120	col. 34:6-9
...comprising: a) discontinuing a daily amount of tetrabenazine; and b) administering an initial daily amount of deutetrabenazine the next day to the human...	The complaint alleges that Alkem's proposed labeling will direct the specific claimed sequence of discontinuing one drug and starting the other on the following day.	¶120	col. 34:10-14
...wherein the daily amount of tetrabenazine is [specific value, e.g., 12.5 mg] and the initial total daily amount of deutetrabenazine is [specific value, e.g., 6 mg]...	The complaint alleges that Alkem's proposed labeling will recommend the specific dose-conversion pairs recited in the claim.	¶120	col. 34:15-34

• Identified Points of Contention:
  • Inducement Questions: The infringement allegation for this method claim hinges on induced infringement Compl. ¶121 A primary point of contention will be whether the language in Alkem's proposed product label rises to the level of actively encouraging, recommending, or promoting the claimed method steps, as required to prove inducement. The court will need to analyze the specific text of the proposed label to determine if it teaches the claimed transition method.
  • Label Carve-Out Questions: A potential defense strategy in such cases is a "carve-out," where a generic manufacturer attempts to omit patented methods of use from its label. This raises the question of whether Alkem has attempted such a carve-out and, if so, whether it is legally sufficient to avoid inducement. The complaint does not provide the proposed label for analysis.

V. Key Claim Terms for Construction

"crystalline d6-tetrabenazine Form I"

• Source: '780 Patent, Claim 1
• Context and Importance: This term is the subject of the composition of matter claim. The definition is critical because polymorphism-the existence of different crystalline forms of the same compound-is common in pharmaceuticals, and different forms can have different properties. Infringement will depend entirely on whether Alkem's product contains the specific polymorph claimed as "Form I."
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent does not appear to have been provided. A party arguing for a broader interpretation might suggest that "Form I" is defined by the presence of the most characteristic peaks, and that the absence of minor peaks or slight shifts in peak positions does not place a sample outside the scope of the claim.
  • Evidence for a Narrower Interpretation: The claim explicitly defines Form I by a list of five specific X-ray diffractogram peaks at specific 2θ values Compl. ¶29 A party arguing for a narrower construction will likely contend that a compound must exhibit all five of these recited peaks within the specified margin of error (±0.2) to meet the claim limitation.

"transitioning a human from tetrabenazine to deutetrabenazine"

• Source: '996 Patent, Claim 1
• Context and Importance: This phrase defines the core action of the asserted method claim. The infringement allegation is for inducement, based on Alkem's proposed product labeling Compl. ¶120 Compl. ¶121 The construction of "transitioning" is therefore central to determining whether the instructions on the label actually teach the patented method.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent's general description refers to "new dosing regimens" and "methods for the treatment" '996 Patent, col. 1:11-16 A party might argue this supports a broad reading of "transitioning" to cover any physician-guided switch from one therapy to another.
  • Evidence for a Narrower Interpretation: Claim 1 itself provides a very specific definition of the transition: "discontinuing a daily amount of tetrabenazine; and administering an initial daily amount of deutetrabenazine the next day" with specific dosage pairings Compl. ¶35 The patent specification further details the "overnight switch" protocol used in clinical trials '996 Patent, FIG. 5 A party arguing for a narrow construction will assert that "transitioning" is strictly limited to this "stop-one-day-start-the-next" sequence with the claimed dose pairings.

VI. Other Allegations

• Indirect Infringement: The complaint alleges active inducement of infringement for all asserted patents, stating that Alkem plans and intends for its products to be used in an infringing manner, particularly by following the instructions on the proposed product labeling (e.g., Compl. ¶111; Compl. ¶121). The complaint also alleges contributory infringement, stating that Alkem knows its products are especially made or adapted for infringing the patents and are not suitable for substantial non-infringing use (e.g., Compl. ¶112; Compl. ¶122).
• Willful Infringement: The complaint alleges that Alkem has acted with "full knowledge" of the patents-in-suit and "without a reasonable basis for believing that it would not be liable for infringing" them (e.g., Compl. ¶114; Compl. ¶124). This allegation is predicated on Alkem's filing of an ANDA with a Paragraph IV certification, which requires the generic applicant to certify against the patents listed in the FDA's Orange Book, thereby establishing pre-suit knowledge of the patents.

VII. Analyst's Conclusion: Key Questions for the Case

• A primary question for the composition patents (e.g., '780, '386, '232, '488, '075, '598) will be evidentiary and factual: does Alkem's proposed generic product, as described in its ANDA, contain the specific crystalline form of deutetrabenazine, fall within the claimed impurity profiles, or embody the specific osmotic-release formulations claimed by Plaintiffs? The outcome for these patents will depend almost entirely on a comparison of the ANDA specifications with the patent claims.
• A central issue for the method of use patents (e.g., '996, '772, '291, '917, '244, '858) will be one of induced infringement: does the language of Alkem's proposed product label, which has not yet been produced, actively instruct or encourage physicians and patients to perform the specific, multi-step methods of dose transitioning, titration, or administration to specific patient populations as claimed in the patents?
• A key legal and strategic question will be one of patent thicket navigation: with twelve patents asserted covering the compound, its formulation, and its methods of use, the case will involve managing a complex web of overlapping claims. This raises the question of whether any single patent or claim group will emerge as the primary driver of the litigation, or if the sheer number of asserted patents will be a strategic factor in itself aimed at complicating the path for a generic entrant.